Residues in the 11 Å channel of histone deacetylase 1 promote catalytic activity: Implications for designing isoform-selective histone deacetylase inhibitors

Journal of Medicinal Chemistry

Volumn 51, Issue 18, 2008, Pages 5542-5551

  Weerasinghe, Sujith V W ^a   Estiu, Guillermina ^b   Wiest, Olaf ^b   Pflum, Mary Kay H ^a  

^a WAYNE STATE UNIVERSITY   (United States)

^b UNIVERSITY OF NOTRE DAME   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE DEACETYLASE 1; HISTONE DEACETYLASE INHIBITOR; ISOENZYME; ENZYME INHIBITOR; HISTONE DEACETYLASE;

ARTICLE; CATALYSIS; DRUG DESIGN; DRUG SELECTIVITY; ENZYME ACTIVE SITE; ENZYME INHIBITION; MOLECULAR DYNAMICS; MOLECULAR MODEL; NUCLEOTIDE SEQUENCE; STRUCTURE ACTIVITY RELATION; CHEMISTRY; DRUG ANTAGONISM; GENETICS; HUMAN; KINETICS; LEUKEMIA CELL LINE; METABOLISM; MUTATION;

CATALYSIS; ENZYME INHIBITORS; HISTONE DEACETYLASES; HUMANS; ISOENZYMES; JURKAT CELLS; KINETICS; MUTATION;

EID: 52449112167     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm800081j     Document Type: Article

References (58)

1. Chenna, R.; Sugawara, H.; Koike, T.; Lopez, R.; Gibson, T. J.; Higgins, D. G.; Thompson, J. D. Multiple sequence alignment with the Clustal series of programs. Nucleic Acids Res. 2003, 31, 3497-500.
2. Grunstein, M. Histone acetylation in chromatin structure and transcription. Nature 1997, 389, 349-352.
3. Dokmanovic, M.; Clarke, C; Marks, P. A. Histone deacetylase inhibitors: overview and perspectives. Mol. Cancer Res. 2007, 5, 981-989.
4. Ryan, Q. C.; Headlee, D.: Acharya, M.; Sparreboom, A.; Trepel, J. B.; Ye, J.; Figg, W. D.; Hwang, K.; Chung, E. J.; Murgo, A.; Melillo, G.; Elsayed, Y.; Monga, M.; Kalnitskiy, M.; Zwiebel, J.; Sausville, E. A. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J. Clin. Oncol. 2005, 23, 3912-3922.
5. Kelly, W. K.; O'Connor, O. A.; Krug, L. M.; Chiao, J. H.; Heaney, M.; Curley, T.; MacGregore-Cortelli, B.; Tong, W.; Secrist, J. P.; Schwartz, L.; Richardson, S.; Chu, E.; Olgac, S.; Marks, P. A.; Scher, H.; Richon, V. M. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J. Clin. Oncol. 2005, 23, 3923-3931.
6. Gregoretti, I.; Lee, Y.-M.; Goodson, H. V. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J. Mol. Biol. 2004, 338, 17.
7. Taunton, J.; Hassig, C. A.; Schreiber, S. L. A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. Science 1996, 272, 408-411.
8. Yang, W.-M.; Inouye, C.; Zeng, Y.; Bearss, D.; Seto, E. Transcriptional repression by YY1 is mediated by interaction with a mammalian homolog of the yeast global regulator RPD3. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 12845-12850.
9. Yang, W. M.; Yao, Y. L.; Sun, J. M.; Davie, J. R.; Seto, E. Isolation and characterization of cDNAs corresponding to an additional member of the human histone deacetylase gene family. J. Biol. Chem. 1997, 272, 28001-28007.
10. Hu, E.; Chen, Z.; Fredrickson, T.; Zhu, Y.; Kirkpatrick, R.; Zhang, G.-F.; Johanson, K.; Sung, C.-M.; Liu, R.; Winkler, J. Cloning and characterization of a novel class I histone deacetylase that functions as a transcription repressor. J. Biol. Chem. 2000, 275, 15254-15264.
11. Van den Wyngaert, I.; de Vries, W.; Kremer, A.; Neefs, J.-M.; Verhasselt, P.; Luyten, W. H. M. L.; Kass, S. U. Cloning and characterization of human histone deactylase 8. FEBS Lett. 2000, 478, 77-83.
12. Grozinger, C. M.; Hassig, C. A.; Schreiber, S. L. Three proteins define a class of human histone deacetylases related to yeast Hda1p. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 4868-4873.
13. Kao, H.-Y.; Downes, M.; Ordentlich, P.; Evans, R. M. Isolation of a novel histone deacetylase reveals that class I and class II deacetylases promote SMRT-mediated repression. Genes Dev. 2000, 14, 55-66.
14. Zhou, X.; Marks, P. A.; Rifkind, R. A.; Richon, V. M. Cloning and characterization of a histone deacetylase, HDAC9. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 10572-10577.
15. Gao, L.; Cueto, M. A.; Asselbergs, F.; Atadja, P. Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. J. Biol. Chem. 2002, 277, 25748-25755.
16. Finnin, M. S.; Donigian, J. R.; Cohen, A.; Richon, V. M.; Rifkind, R. A.; Marks, P. A.; Pavletich, N. P.; Breslow, R. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 1999, 401, 188-193.
17. Corminboeuf, C.; Hu, P.; Tuckerman, M. E.; Zhang, Y. Unexpected deacetylation mechanism suggested by a density functional theory QM/MM study of histone-deacetylase-like protein. J. Am. Chem. Soc. 2006, 128, 4530-4531.
18. Lagger, G.; O'Carroll, D.; Rembold, M.; Khier, H.; Tischler, J.; Weitzer, G.; Schuettengruber, B.; Hauser, C.; Brunmeir, R.; Jenuwein, T.; Seiser, C. Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J. 2002, 21, 2672-2681.
19. Zupkovitz, G.; Tischler, J.; Posch, M.; Sadzak, I.; Ramsauer, K.; Egger, G.; Grausenburger, R.; Schweifer, N.; Chiocca, S.; Decker, T.; Seiser, C. Negative and positive regulation of gene expression by mouse histone deacetylase 1. MoI. Cell. Biol. 2006, 26, 7913-7928.
20. Glaser, K. B.; Li, J.; Staver, M. J.; Wei, R.Q.; Albert, D. H.; Davidsen, S. K. Role of class I and class II histone deacetylases in carcinoma cells using siRNA. Biochem. Biophvs. Res. Commun. 2003, 310, 529-536.
21. Hoshikawa, Y.; Kwon, H. J.; Yoshida, M.; Horinouchi, S.; Beppu, T. Trichostatin A induces morphological changes and gelsolin expression by inhibiting histone deacetylase in human carcinoma cell lines. Exp. Cell Res. 1994, 214, 189-197.
22. Bartl, S.; Taplick, J.; Lagger, G.; Khier, H.; Kuchler, K.; Seiser, C. Identification of mouse histone deacetylase 1 as a growth factor-inducible gene. Mol. Cell. Biol. 1997, 17, 5033-5043.
23. You, A.; Tong, J. K.; Grozinger, C. M.; Schreiber, S. L. CoREST is an integral component of the CoREST-human histone deacetylase complex. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 1454-1458.
24. Humphrey, G. W.; Wang, Y.; Russanova, V. R.; Hirai, T.; Qin, J.; Nakatani, Y.; Howard, B. H. Stable histone deacetylase complexes distinguished by the presence of SANT domain proteins CoREST/kiaa0071 and Mta-L1. J. Biol. Chem. 2001, 276, 6817-6824.
25. Hassig, C. A.; Fleischer, T. C.; Billin, A. N.; Schreiber, S. L.; Ayer, D. E. Histone deacetylase activity is required for full transcriptional repression by mSin3A. Cell 1997, 89, 341-347.
26. Zhang, Y.; Iratni, R.; Erdjument-Bromage, H.; Tempst, P.; Reinberg, D. Histone deactylases and SAP18, a novel polypeptide, are components of a human Sin3 complex. Cell 1997, 89, 357-364.
27. Zhang, Y.; Sun, Z.-W.; Iratni, R.; Erdjument-Bromage, H.; Tempst, P.; Hampsey, M.; Reinberg, D. SAP30, a novel protein conserved between human and yeast, is a component of a histone deacetylase complex. Mol. Cell 1998, 1, 1021-1231.
28. Alland, L.; David, G.; Shen-Li, H.; Potes, J.; Muhle, R.; Lee, H.-C.; Hou, H., Jr.; Chen, K.; DePinho, R. A. Identification of mammalian Sds3 as an integral component of the Sin3/histone deacetylase corepressor complex. Mol. Cell. Biol. 2002, 22, 2743-2750.
29. Laherty, C. D.; Yang, W.-M.; Sun, J.-M.; Davie, J. R.; Seto, E.; Eisenman, R. N. Histone deacetylases associated with the mSin3 corepressor mediate Mad transcriptional repression. Cell 1997, 89, 349.
30. Tong, J. K.; Hassig, C. A.; Schnitzler, G. R.; Kingston, R. E.; Schreiber, S. L. Chromatin deacetylation by an ATP-dependent nucleosome remodelling complex. Nature 1998, 395, 917-921.
31. Xue, Y.; Wong, J.; Moreno, G. T.; Young, M. K.; Côté, J.; Wang, W. NURD, a novel complex with both ATP-dependent chromatin-remodeling and histone deacetylase activities. Mol. Cell 1998, 2, 851-861.
32. Zhang, Y.; Ng, H.-H.; Erdjument-Bromage, H.; Tempst, P.; Bird, A.; Reinberg, D. Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation. Genes Dev. 1999, 13, 1924-1935.
33. Vannini, A.; Volpari, C.; Filocamo, G.; Casavola, E. C.; Brunetti, M.; Renzoni, D.; Chakravarty, P.; Paolini, C.; De Francesco, R.; Gallinari, P.; Steinkühler, C.; Di Marco, S. Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 15064-15069.
34. Karagiannis, T. C.; El-Osta, A. Will broad-spectrum histone deacetylase inhibitors be superseded by more specific compound? Leukemia 2006, 21, 61-65.
35. Bieliauskas, A.; Weerasinghe, S. V. W.; Pflum, M. K. H. Structural requirements of HDAC inhibitors: SAHA analogs functionalized adjacent to the hydroxamic acid. Bioorg. Med. Chem. Lett. 2007, 17, 2216-2219.
36. Beckers, T.; Burkhardt, C.; Wieland, H.; Gimmnich, P.; Ciossek, T.; Maier, T.; Sanders, K. Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group. Int. J. Cancer 2007, 121, 1138-1148.
37. Wang, D.-F.; Helquist, P.; Wiech, N. L.; Wiest, O. Toward selective histone deacetylase inhibitor design: homology modeling, docking studies, and molecular dynamics simulations of human class I histone deacetylases. J. Med. Chem. 2005, 48, 6936-6947.
38. Wang, D.-F.; Wiest, O.; Helquist, P.; Lan-Hargest, H.-Y.; Wiech, N. L. On the function of the 14 A long internal cavity of histone deacetylase-like protein: implications for the design of histone deacetylase inhibitors. J. Med. Chem. 2004, 47, 3409-3417.
39. Estiu, G.; Greenberg, E.; Harrison, C. B.; Kwiatkowski, N. P.; Mazitschek, R.; Bradner, J. E.; Wiest, O. Structural origin of selectivity in class II-selective histone deacetylase inhibitors. J. Med. Chem. 2008, 51, 2898-2906.
40. Somoza, J. R.; Skene, R. J.; Katz, B. A.; Mol, C.; Ho, J. D.; Jennings, A. J.; Luong, C.; Arvai, A.; Buggy, J. J.; Chi, E.; Tang, J.; Sang, B.-C.; Verner, E.; Wynands, R.; Leahy, E. M.; Dougan, D. R.; Snell, G.; Navre, M.; Knuth, M. W.; Swanson, R. V.; McRee, D. E.; Tari, L. W. Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. Structure 2004, 12, 1325-1334.
41. Grozinger, C. M.; Schreiber, S. L. Deacetylase enzymes: biological functions and the use of small-molecule inhibitors. Chem. Biol. 2002, 9, 3-16.
42. Hassig, C. A.; Tong, J. K.; Fleischer, T. C.; Owa, T.; Grable, P. G.; Ayer, D. E.; Schreiber, S. L. A role for histone deacetylase activity in HDACl-mediated transcriptional repression. Proc. Natl. Acad. Sci. U.S.A 1998, 95, 3519-3524.
43. Pflum, M. K. H.; Tong, J. K.; Lane, W. S.; Schreiber, S. L. Histone deacetylase 1 phosphorylation promotes enzymatic activity and complex formation. J. Biol. Chem. 2001, 276, 47733-47741.
44. Hildmann, C.; Wegener, D.; Riester, D.; Hempel, R.; Schober, A.; Merana, J.; Giurato, L.; Guccione, S.; Nielsen, T. K.; Ficner, R.; Schwienhorst, A. Substrate and inhibitor specificity of class 1 and class 2 histone deacetylases. J. Biotechnol. 2006, 124, 258-270.
45. Riester, D.; Hildmann, C.; Grünewald, S.; Beckers, T.; Schwienhorst, A. Factors affecting the substrate specificity of histone deacetylases. Biochem. Biophys. Res. Commun. 2007, 357, 439-445.
46. Li, J.; Staver, M. J.; Curtin, M. L.; Holms, J. H.; Frey, R. R.; Edalji, R.; Smith, R.; Michaelides, M. R.; Davidsen, S. K.; Glaser, K. B. Expression and functional characterization of recombinant human HDAC1 and HDAC3. Life Sci. 2004, 74, 2693-2705.
47. Schultz, B. E.; Misialek, S.; Wu, J.; Tang, J.; Conn, M. T.; Tahilramani, R.; Wong, L. Kinetics and comparative reactivity of human class I and class IIb histone deacetylases. Biochemistry 2004, 43, 11083-11091.
48. Cunningham, B. C.; Wells, J. A. High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis. Science 1989, 244, 1081-1085.
49. Leung, H. B.; Schramm, V. L. A mutant AMP nucleosidase. Purification, properties, and in vivo turnover of the protein. J. Biol. Chem. 1981, 256, 12823-12829.
50. max mutant of AMP nucleosidase by the application of heavy-atom kinetic isotope effects. Biochemistry 1991, 30, 4586-4594.
51. Liu, Y.; Shah, K.; Yang, F.; Witucki, L.; Shokat, K. M. A molecular gate which controls unnatural ATP analogue recognition by the tyrosine kinase v-Src. Bioorg. Med. Chem. 1998, 6, 1219-1226.
52. Northrop, J. P.; Ullman, K. S.; Crabtree, G. R. Characterization of the nuclear and cytoplasmic components of the lymphoid-specific nuclear factor of activated T cells (NF-AT) complex. J. Biol. Chem. 1993, 268, 2917-2923.
53. DeLano, W. L. The PyMOL Molecular Graphics System; Delano Scientific: San Carlos, CA, 2002.
54. Case, D. A.; Darden, T. A.; Cheatham, T. E., III; Simmerling, C. L.; Wang, J.; Duke., R. E.; Luo, R.; Merz, K. M.; Wang, B.; Pearlman, D. A.; Crowley, M.; Brozell, S.; Tsui, V.; Gohlke, H.; Mongan, J.; Hornak, V.; Cui, G.; Beroza, P.; Schafmeister, C.; Caldwell, J. W.; Ross, W. S.; Kollman, P. A. AMBER 8; Univeristy of California: San Fransisco, 2004.
55. Stote, R. H.; Karplus, M. Zinc binding in proteins and solution: a simple but accurate nonbonded representation. Proteins 1995, 23, 12-31.
56. van Gunsteren, W. F.; Berendsen, H. J. C. Algorithms for macromolecular dynamics and constrained dynamics. Mol. Phys. 1977, 34, 1311.
57. Essman, U.; Perera, L.; Berkowitz, M. L.; Darden, T.; Lee, H.; Pedersen, L. G. Accuracy and efficiency of the particle mesh Ewald method. J. Chem. Phys. 1995, 103, 8557-8593.
58. Allen, M. P.; Tildesley, D. J. Computer Simulation of Liquids; Claredon Press: Oxford, U.K., 1989.